HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES
申请人:BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
公开号:EP1309596A2
公开(公告)日:2003-05-14
US6489328B2
申请人:——
公开号:US6489328B2
公开(公告)日:2002-12-03
US6844435B2
申请人:——
公开号:US6844435B2
公开(公告)日:2005-01-18
[EN] HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES<br/>[FR] COMPOSES HETEROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE TYROSINE KINASES
申请人:BOEHRINGER INGELHEIM PHARMA
公开号:WO2002014319A2
公开(公告)日:2002-02-21
Disclosed are novel compounds of formula (I) (see formula I as described in specification) wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.
Heterocyclic compounds useful as inhibitors of tyrosine kinases
申请人:——
公开号:US20020119975A1
公开(公告)日:2002-08-29
Disclosed are novel compounds of formula (I):
1
wherein Ar
1
, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.